Ketodarolutamide (original) (raw)
Ketodarolutamide (developmental code names ORM-15341, BAY-1896953) is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of darolutamide (ODM-201, BAY-1841788), an NSAA which is used in the treatment of prostate cancer in men. Similarly to its parent compound, darolutamide acts as a highly selective, high-affinity, competitive silent antagonist of the androgen receptor (AR). Both agents show much higher affinity and more potent inhibition of the AR relative to the other NSAAs enzalutamide and apalutamide, although they also possess much shorter and comparatively less favorable elimination half-lives. They have also been found not to activate certain mutant AR variants that enzalutamide and apalutamide do activate. Both darolutamide and ketodarolutamide show limited central
| Property | Value |
|---|---|
| dbo:abstract | Ketodarolutamide (developmental code names ORM-15341, BAY-1896953) is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of darolutamide (ODM-201, BAY-1841788), an NSAA which is used in the treatment of prostate cancer in men. Similarly to its parent compound, darolutamide acts as a highly selective, high-affinity, competitive silent antagonist of the androgen receptor (AR). Both agents show much higher affinity and more potent inhibition of the AR relative to the other NSAAs enzalutamide and apalutamide, although they also possess much shorter and comparatively less favorable elimination half-lives. They have also been found not to activate certain mutant AR variants that enzalutamide and apalutamide do activate. Both darolutamide and ketodarolutamide show limited central nervous system distribution, indicating peripheral selectivity, and little or no inhibition or induction of cytochrome P450 enzymes such as CYP3A4, unlike enzalutamide and apalutamide. (en) |
| dbo:casNumber | 1297537-33-7 |
| dbo:class | dbr:Nonsteroidal_antiandrogen |
| dbo:fdaUniiCode | 9EPS75QMTL |
| dbo:pubchem | 52919826 |
| dbo:thumbnail | wiki-commons:Special:FilePath/ORM-15341.svg?width=300 |
| dbo:wikiPageExternalLink | https://www.orion.fi/globalassets/documents/rd/congress-posters/aacr-2014-odm-201-ar-mutation-data.pdf |
| dbo:wikiPageID | 54521251 (xsd:integer) |
| dbo:wikiPageLength | 5996 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1075451128 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Potency_(pharmacology) dbr:Mutant dbr:Androgen_receptor dbr:Cytochrome_P450 dbc:Chlorobenzenes dbc:Human_drug_metabolites dbr:Competitive_antagonist dbr:Elimination_half-life dbr:Enzalutamide dbr:Enzyme dbr:Apalutamide dbr:Prostate_cancer dbc:Hormonal_antineoplastic_drugs dbc:Nonsteroidal_antiandrogens dbc:Peripherally_selective_drugs dbr:Active_metabolite dbr:Distribution_(pharmacology) dbc:Carboxamides dbc:Pyrazoles dbr:Darolutamide dbr:Central_nervous_system dbr:Enzyme_induction dbc:Nitriles dbr:Affinity_(pharmacology) dbr:Binding_selectivity dbr:CYP3A4 dbr:Nonsteroidal_antiandrogen dbr:Enzyme_inhibition dbr:Parent_compound dbr:Silent_antagonist dbr:Peripheral_selectivity |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 1297537 (xsd:integer) |
| dbp:chemspiderid | 38772344 (xsd:integer) |
| dbp:cl | 1 (xsd:integer) |
| dbp:class | dbr:Nonsteroidal_antiandrogen |
| dbp:eliminationHalfLife | 36000.0 |
| dbp:h | 17 (xsd:integer) |
| dbp:iupacName | 3 (xsd:integer) |
| dbp:n | 6 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 52919826 (xsd:integer) |
| dbp:smiles | C[C@@H]NCC3=CCCC (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | GMBPVBVTPBWIKC-NSHDSACASA-N (en) |
| dbp:synonyms | ORM-15341; BAY-1896953 (en) |
| dbp:unii | 9 (xsd:integer) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Androgen_receptor_modulators dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Short_description |
| dcterms:subject | dbc:Chlorobenzenes dbc:Human_drug_metabolites dbc:Hormonal_antineoplastic_drugs dbc:Nonsteroidal_antiandrogens dbc:Peripherally_selective_drugs dbc:Carboxamides dbc:Pyrazoles dbc:Nitriles |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Ketodarolutamide (developmental code names ORM-15341, BAY-1896953) is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of darolutamide (ODM-201, BAY-1841788), an NSAA which is used in the treatment of prostate cancer in men. Similarly to its parent compound, darolutamide acts as a highly selective, high-affinity, competitive silent antagonist of the androgen receptor (AR). Both agents show much higher affinity and more potent inhibition of the AR relative to the other NSAAs enzalutamide and apalutamide, although they also possess much shorter and comparatively less favorable elimination half-lives. They have also been found not to activate certain mutant AR variants that enzalutamide and apalutamide do activate. Both darolutamide and ketodarolutamide show limited central (en) |
| rdfs:label | Ketodarolutamide (en) |
| owl:sameAs | wikidata:Ketodarolutamide https://global.dbpedia.org/id/2YKRd |
| prov:wasDerivedFrom | wikipedia-en:Ketodarolutamide?oldid=1075451128&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/ORM-15341.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Ketodarolutamide |
| is dbo:wikiPageRedirects of | dbr:ORM-15341 dbr:BAY-1896953 dbr:BAY1896953 dbr:BAY_1896953 dbr:Keto-darolutamide dbr:ORM-15,341 dbr:ORM15,341 dbr:ORM15341 dbr:ORM_15,341 dbr:ORM_15341 dbr:Oxo-darolutamide dbr:Oxodarolutamide |
| is dbo:wikiPageWikiLink of | dbr:ORM-15341 dbr:Darolutamide dbr:BAY-1896953 dbr:BAY1896953 dbr:BAY_1896953 dbr:Keto-darolutamide dbr:ORM-15,341 dbr:ORM15,341 dbr:ORM15341 dbr:ORM_15,341 dbr:ORM_15341 dbr:Oxo-darolutamide dbr:Oxodarolutamide |
| is dbp:metabolites of | dbr:Darolutamide |
| is foaf:primaryTopic of | wikipedia-en:Ketodarolutamide |
